True To Its Word, LivaNova Sheds CRM – To MicroPort
Executive Summary
One of the cleanest and swiftest M&A deals of recent months was the twinning of LivaNova's CRM business with MicroPort's enhanced ambitions in a $10 billion global market. What now for these two medtech innovators?
You may also be interested in...
LivaNova To Buy TandemLife For Up to $250m, Adding Complementary Cardiac Surgery
London-based cardiac surgery and neuroscience group LivaNova PLC is buying privately held Pittsburgh-based TandemLife in a deal worth up to $250m. TandemLife develops advanced cardiopulmonary temporary support systems that are complementary to LivaNova's cardiac surgery segments.
Medtech 2018: The Place For Innovation As Value-based Health Care Gains Momentum
2017 was a watershed year in many respects, politically, economically and commercially for many players in the medtech field. Where will the opportunities lie in 2018, will breakthrough medtech innovation still have a place among providers often riding on fumes when it comes to budgets, and is it all as bad as some would make out?
LivaNova Builds Strategic Base And Commercial Case To Silence Skeptics
Medical innovator LivaNova has a new stated focus: it won’t go outside the head and the heart when it comes to potential M&A and technology development projects. It has set out short- and longer-term solutions to boost sales and/or profitability in its neuromodulation and cardio franchises. What is certain is that eight months into his tenure as CEO, Damien McDonald is stamping his imprint all over LivaNova.